Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.

Abstract: Novel polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: A drug for the treatment of rheumatoid arthritis, which comprises as an active ingredient a monoclonal antibody which recognizes specifically extracellular region of human VLA-2. Preferable drug for the treatment of rheumatoid arthritis comprises as an active ingredient a monoclonal antibody which recognizes specifically extracellular region of human VLA-2, .alpha. chain. The above drug for the treatment of rheumatoid arthritis can suppress swelling due to arthritis in rheumatoid arthritis with low toxicity and hence is useful for the treatment of rheumatoid arthritis.

Abstract: The present invention provides a human mitochondrial membrane protein (HuTIM17) and polynucleotides which identify and encode HuTIM17. The invention also provides expression vectors and host cells and a method for producing HuTIM17. The invention also provides for antibodies or antagonists specifically binding HuTIM17, and their use in the prevention and treatment of cancer. The invention also provides diagnostic assays. The invention also provides for the use of HuTIM17 in identifying antifungal and antiprotozoal therapeutics.

Abstract: The present invention relates to receptors for advanced glycosylation endproducts derived from rat liver membranes, and that specifically comprise proteins determined to possess molecular masses of about 90 kD and 60 kD, respectively, as assessed by migration during SDS-PAGE. Partial N-terminal sequences have been determined and diagnostic and therapeutic agents, compositions and methods are proposed. Antibodies to the 90 kD and 60 kD receptor proteins are disclosed.

Abstract: The thymidine kinase-lacking hybridoma of the invention has resistance to oaubain and an Ig-producing ability and is formed by fusing a chicken B lymphoblast cell with an immunized chicken spleen cell. The hybridoma can be used as parental cell line for cell fusion, and the fused cell is excellent in the production of IgG.

Abstract: The present invention provides a human tumor suppressor (TUPRO-2) and polynucleotides which identify and encode TUPRO-2. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for treating diseases associated with expression of TUPRO-2.

Abstract: Methods for diagnosing thrombosis are disclosed. The methods comprise contacting a biological fluid of a subject with an antibody which binds specifically to the peptide liberated when thrombin receptors are activated.

Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

Abstract: The present invention is directed to a method of immunoassay of asialoglycoprotein receptors (AGPR) by bringing a specimen into contact with a monoclonal antibody that recognizes AGPR, wherein the pH of a diluted specimen solution is adjusted from 5 to 7 or phenol is added to a solution of an enzyme-labeled antibody. This method is excellent in the sensitivity and accuracy of AGPR assay and can be applied also to the screening of hepatopathy remedies.

Abstract: The invention relates to in vivo peripheralization of CD34.sup.+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.

Abstract: Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine cell hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.

Abstract: Novel bifunctional reagents useful in reducing the biological effect of an undesirable blood-borne agent are provided. The reagents comprise conjugates of a first binding member specific for a blood-borne agent having a detrimental biological activity in a mammalina host, such as a growth factor, coagulation factor, enzyme, toxin, drug of abuse, microbe, autoreactive immune cell, infected or tumorous cell, joined to an second binding member specific for an anchor, where the anchor is a long-lived blood component, including cells, such as a erythrocyte, platelet or endothelial cell and serum proteins, such as albumin, ferritin, or steroid binding proteins. These conjugates find therapeutic use by coupling the agent and the blood component and thereby reducing the biological activity or effective concentration of free agent, modulating the volume of distribution of the agent, targeting the agent to sites of enhanced immune response, or facilitating agent clearance from the bloodstream.

Abstract: A mammal is immunized by using an antigen of a peptide having an amino acid sequence existing in a region having low homology to amino acid sequences of tyrosinase-related proteins but included in an amino acid sequence of human tyrosinase, and then the spleen cells of the mammal is fused with cultured cells to prepare a hybridoma producing monoclonal antibody which binds to human tyrosinase and mouse tyrosinase but does not bind to the tyrosinase-related proteins.

Abstract: This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to create partially humanized whole antibody molecules. These chimeric anti-EGFR antibodies contain constant regions of human immunoglobulins, and can be used as well as the single-chain Fvs as agents for the diagnosis and therapy of human tumors.

Abstract: The present invention provides a first polypeptide fragment of lipopolysaccharide (LPS) binding protein (LBP) which binds to lipopolysaccharide, but prevents the LPS:LBP complex from either transferring LPS to CD14 or promoting the formation of an LPS:CD14 complex and a second polypeptide fragment of LBP which binds to CD14 receptor to inhibit binding of LPS:LBP complex to the CD14 receptor. Also included are methods of ameliorating symptoms of sepsis in a subject by administration of a LBP polypeptide of the invention, or administration of antibody to LBP polypeptide or anti-idiotype antibody.

Abstract: The invention relates to isolated human mesenchymal stem cells, a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or "MSCs"), and characterization of (including by cytokine expression profiling) and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Further disclosed are monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.

Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.

Abstract: The present invention is related to the field of receptor molecules and complexes. More particularly, the present invention is related to a new polypeptide receptor for interleukin-2 having a molecular weight of about 70-75,000, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide, and recombinant interleukins capable of binding to the new receptor. Various applications of the p70-75 receptor, the anti-p70-75 antibodies and IL-2W.sub.1 and IL2W.sub.2 have also been described.

Abstract: Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding LAM-1, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-toxic pharmaceutical carrier substance.